狂犬病单克隆抗体与疫苗暴露后预防方案在III级潜在暴露患者中的研究:一项4期、开放标签、随机、阳性对照试验
该研究在印度15家三级医院开展4期开放标签随机对照试验,比较狂犬病单克隆抗体(RmAb)联合纯化Vero细胞狂犬病疫苗(PVRV)与马狂犬病免疫球蛋白(ERIG)联合PVRV的暴露后预防方案。共治疗3994例III级暴露患者,随访1年,RmAb组与ERIG组第14天中和抗体几何平均浓度分别为16.05 IU/mL和13.48 IU/mL,无患者发生狂犬病,RmAb安全且耐受性良好。
要点
- RmAb联合PVRV方案在III级狂犬病暴露患者中安全且耐受性良好。
- 第14天RmAb组中和抗体几何平均浓度为16.05 IU/mL,ERIG组为13.48 IU/mL。
- 1年随访期间无患者发生狂犬病。
核心结论
- RmAb安全且耐受性良好,并显示出对狂犬病的保护效力。
- 含RmAb联合PVRV的暴露后预防方案具有免疫原性,且免疫反应长期持续。
研究设计与样本
- 该研究为4期、开放标签、随机、阳性对照试验,在印度15家三级医院开展。
- 纳入年龄2岁及以上、由疑似狂犬病动物导致WHO III级狂犬病暴露的患者,暴露需在入组前72小时内,或面部、颈部、手或手指暴露需在入组前24小时内。
- 参与者按3:1随机分配接受RmAb(Rabishield)联合PVRV(Rabivax-S)或ERIG(Equirab)联合PVRV,每组内再按1:1随机分配接受皮内或肌内PVRV。
- 共治疗3994例参与者(3001例男性,993例女性),其中RmAb联合PVRV组2996例,ERIG联合PVRV组998例;3622例(90.7%)完成1年随访。
- 主要结局为免疫后365天内治疗相关严重不良事件,在安全性分析集中分析。
主要发现
- 11例不良事件被认为与RmAb联合PVRV有因果关系,17例被认为与ERIG联合PVRV方案有因果关系;大多数不良事件为轻度且短暂。
- RmAb组发生7例严重不良事件,均与治疗无因果关系;ERIG组报告1例有因果关系的严重不良事件。
- 第14天,RmAb组中和抗体几何平均浓度增至16.05 IU/mL(95% CI 13.25-19.44),ERIG组为13.48 IU/mL(95% CI 9.51-19.11),点估计值为1.19(95% CI 0.82-1.72)。
- 1年随访期间无患者发生狂犬病。
关键数值与推荐
- RmAb剂量为3.33 IU/kg,ERIG剂量为40 IU/kg,仅在第0天按WHO 2018建议浸润注射于伤口内及周围。
- PVRV肌内接种1.0 mL(第0、3、7、14和28天),或皮内接种0.1 mL加0.1 mL(第0、3、7和28天)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rabies is almost invariably fatal. A rabies monoclonal antibody (RmAb) was approved in India in 2016 for passive prophylaxis. This post-marketing study aimed to evaluate the long-term safety, immunogenicity, and efficacy of a post-exposure prophylaxis (PEP) regimen containing RmAb. METHODS: This phase 4, open-label, randomised, active-controlled study was conducted at 15 tertiary care hospitals in India. Patients aged 2 years or older with WHO category 3 rabies exposure by a suspected rabid animal were eligible if the exposure occurred less than 72 h before enrolment, or less than 24 h before enrolment for exposures to the face, neck, hand, or fingers. Participants were randomly assigned (3:1) to receive either RmAb (Rabishield; Serum Institute of India, Pune, India) plus a purified Vero cell rabies vaccine (PVRV; Rabivax-S) or equine rabies immunoglobulin (ERIG; Equirab) plus PVRV as PEP. In each treatment group, patients were further randomly assigned (1:1) to receive PVRV either intradermally or intramuscularly. Study group allocation was done using a permuted block design with random block sizes of eight. A central randomisation list was generated before the study start and randomisation was performed with an interactive web response system. Participants and site personnel were not masked to group assignment. RmAb (3·33 IU/kg) and ERIG (40 IU/kg) were infiltrated into and around the wounds only on day 0 as per WHO 2018 recommendations. PVRV was administered 1·0 mL intramuscularly (days 0, 3, 7, 14, and 28) or 0·1 mL plus 0·1 mL intradermally (days 0, 3, 7, and 28). The primary outcome was treatment-related serious adverse events up to 365 days after immunisation, analysed in the safety analysis set (all participants who received at least one dose of vaccine with treatment). Geometric mean concentrations of rabies virus neutralising antibody were measured in a subset of patients. This study is registered with Clinical Trial Registry-India (CTRI/2019/06/019622) and is completed. FINDINGS: 4059 participants were enrolled between Aug 21, 2019, and March 31, 2022, and randomly assigned. A total of 3994 participants (3001 male, 993 female) were treated (2996 RmAb plus PVRV, 998 ERIG plus PVRV), of which 3622 (90·7%) participants completed the 1-year follow-up. 11 adverse events were considered causally related to RmAb plus PVRV and 17 were considered causally related to the ERIG plus PVRV regimen. Most adverse events were mild and transient. Seven serious adverse events occurred in the RmAb group and all were causally unrelated. One causally related serious adverse event was reported in the ERIG group. On day 14, the geometric mean concentrations increased to 16·05 IU/mL (95% CI 13·25-19·44) in the RmAb group and 13·48 IU/mL (9·51-19·11) in the ERIG group (point estimate 1·19 [95% CI 0·82-1·72]). No patient developed rabies during the 1-year follow-up period. INTERPRETATION: RmAb was safe and well tolerated and showed protective efficacy against rabies. A PEP regimen containing RmAb plus PVRV was immunogenic with long-term persistence of immune response. FUNDING: Serum Institute of India.
引用
- Kulkarni PS, Potey AV, Kapse D, et al. Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial. Lancet. 2025. PMID: 40783290. doi:10.1016/S0140-6736(25)00735-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。